论文部分内容阅读
目的探讨利福霉素钠治疗呼吸道感染的临床疗效。方法 50例成人呼吸道感染患者,随机分成2组,利福霉素钠治疗组(30例)连续10d静脉滴注利福霉素钠0.5g,1次/d;头孢噻肟钠组(20例)静滴头孢噻肟钠4.0g,1次/d,观察两组经过抗炎治疗后临床症状和体征改善情况。结果利福霉素钠治疗组有效率96.6%,头孢噻肟钠组有效率65.0%,两组对比有统计学意义(p<0.05)。结论利福霉素钠治疗呼吸道感染临床疗效高,显效快,不良反应小,是治疗呼吸道感染的理想药物之一。
Objective To investigate the clinical efficacy of rifamycin sodium in the treatment of respiratory tract infections. Methods Fifty adult patients with respiratory tract infection were randomly divided into two groups. The rifamycin sodium group (n = 30) received rifamycin sodium 0.5 g once daily for 10 days, and the cefotaxime sodium group (n = 20) ) Intravenous cefotaxime sodium 4.0g, 1 / d, observed after anti-inflammatory treatment of two groups of clinical symptoms and signs of improvement. Results Rifamycin sodium treatment group was 96.6%, cefotaxime sodium group 65.0%, the two groups were statistically significant (p <0.05). Conclusions Rifamycin sodium is one of the ideal drugs for the treatment of respiratory tract infections in the treatment of respiratory tract infections with high efficacy, fast onset of response and little adverse reactions.